Zomedica Pharmaceuticals (ZOM) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Zomedica Pharmaceuticals has announced a record-breaking revenue of $7.3 million for Q4 and $25.2 million for the full year of 2023, marking a significant 33% annual growth. The company attributes this success to the early adoption of new products in its Diagnostics segment and solid performance in Therapeutic Devices. Zomedica, maintaining a strong 69% gross margin and a robust liquidity position of $100.5 million, is poised for continued growth in 2024.
For further insights into ZOM stock, check out TipRanks’ Stock Analysis page.
